Corporate News Report

Pharmacyte Biotech (PMCB) has experienced a modest upward movement in the market, trading 1.49 % higher during the 24‑hour period that concluded at 08:22 PM Central Europe on Thursday, 22 nd. The current trading price stands at approximately USD 0.35 on major exchanges.

At present, 10.7 million shares of Pharmacyte Biotech remain available for purchase. The company’s market capitalization has been calculated at USD 3.7 million, and the total trading volume over the last 24 hours reached roughly USD 17.6 k. Compared to the close of the previous month, the stock has declined by 24.25 %.

A technical indicator, the 200‑day simple moving average, is currently positioned at USD 0.66. Over the past 52 weeks, the highest recorded price was USD 1.51 on 12 May 2025, while the lowest price reached USD 0.33 on 15 September 2026.

Recent Performance of Peer Stocks

  • Phionx (900100.KS): Up 0.61 % to KRW 1,096, with a market capitalization of KRW 5.8 billion.
  • Nuburu (BURU): Down 5.22 % to USD 0.41, market cap of USD 4.1 million. Nuburu Inc. has announced the acquisition of a controlling stake in the Italian vehicle‑engineering firm Tekne, securing 70 % ownership and a further agreement to acquire an additional 67 % of shares. The transaction, finalized on 15 October 2026, involves an estimated purchase price of €5.2 million and a structured earn‑out tied to Tekne’s future revenues. A capital contribution of nearly €30 million will reinforce Tekne’s equity base without diluting existing shareholders. Integration plans will utilize Tekne’s engineering and manufacturing facilities for both defense and emergency‑response vehicle production, while aligning Nuburu’s software orchestration platform with Tekne’s capabilities.
  • Azitra (AZTR): Down 39.2 % to USD 0.07, market cap of USD 4.3 million.
  • Cbdmd (YCBD): Down 2.07 % to USD 0.37, market cap of USD 4.3 million.
  • Liminatus Pharma (LIMN): Down 3.11 % to USD 3.1, market cap of USD 4.3 million.

Company Overview

Pharmacyte Biotech, Inc. operates in Laguna Hills, United States, specializing in live‑cell encapsulation technology to develop treatments for cancer and diabetes. The company’s services are primarily offered within California. Pharmacyte Biotech’s official website is www.pharmacyte.com , and it is listed on the Nasdaq stock exchange.